

# Furio Pacini

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8452310/publications.pdf>

Version: 2024-02-01

106  
papers

30,264  
citations

61945

43  
h-index

39638

94  
g-index

115  
all docs

115  
docs citations

115  
times ranked

15484  
citing authors

#	ARTICLE	IF	CITATIONS
1	2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer?. European Thyroid Journal, 2022, 11, .	1.2	62
2	Postsurgical radioiodine ablation in low-risk differentiated thyroid cancer. Lancet Diabetes and Endocrinology,the, 2022, , .	5.5	0
3	Vemurafenib may overcome TNF-related apoptosis-inducing ligand (TRAIL) resistance in anaplastic thyroid cancer cells. Endocrine, 2020, 67, 117-123.	1.1	6
4	Response Letter to the Editor from Edmundo Avila-Hipolito: "Long-Term Effects of Radioiodine in Toxic Multinodular Goiter: Thyroid Volume, Function, and Autoimmunity" Journal of Clinical Endocrinology and Metabolism, 2020, 105, .	1.8	1
5	Long-Term Clinical Outcome in Familial and Sporadic Papillary Thyroid Carcinoma. European Thyroid Journal, 2020, 9, 213-220.	1.2	8
6	Does Microscopic Extrathyroidal Extension Confer a Higher Risk of Recurrence in Patients With Well-Differentiated Thyroid Cancer?. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3016-e3017.	1.8	2
7	Long-term Effects of Radioiodine in Toxic Multinodular Goiter: Thyroid Volume, Function, and Autoimmunity. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2464-e2470.	1.8	11
8	Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer. Endocrine, 2019, 64, 122-129.	1.1	39
9	Management of Subclinical Hypothyroidism in Pregnancy: A Comment from the Italian Society of Endocrinology and the Italian Thyroid Association to the 2017 American Thyroid Association Guidelines" "The Italian Way" Thyroid, 2018, 28, 551-555.	2.4	24
10	Long-term strategies for thyroid health monitoring after nuclear accidents: recommendations from an Expert Group convened by IARC. Lancet Oncology, The, 2018, 19, 1280-1283.	5.1	23
11	Preferred strategy for postsurgical thyroid ablation in low-risk thyroid cancer. Lancet Diabetes and Endocrinology,the, 2018, 6, 590-591.	5.5	1
12	Prospective Validation of ATA and ETA Sonographic Pattern Risk of Thyroid Nodules Selected for FNAC. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2362-2368.	1.8	19
13	Endpoints for screening thyroid cancer in the Republic of Korea: thyroid specialists'™ perspectives. Journal of Endocrinological Investigation, 2017, 40, 689-690.	1.8	0
14	Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab. Endocrine, 2017, 58, 535-541.	1.1	33
15	Diagnostic Value of Circulating microRNA-95 and -190 in the Differential Diagnosis of Thyroid Nodules: A Validation Study in 1000 Consecutive Patients. Thyroid, 2017, 27, 1053-1057.	2.4	16
16	Prognostic indicators for papillary thyroid carcinoma. Expert Review of Endocrinology and Metabolism, 2017, 12, 101-108.	1.2	7
17	Bariatric Surgery Reduces Serum Anti-mullerian Hormone Levels in Obese Women With and Without Polycystic Ovarian Syndrome.. Obesity Surgery, 2017, 27, 1750-1754.	1.1	34
18	Which patient with thyroid cancer deserves systemic therapy and when?. Best Practice and Research in Clinical Endocrinology and Metabolism, 2017, 31, 291-294.	2.2	14

#	ARTICLE	IF	CITATIONS
19	DIO2 Thr92Ala Reduces Deiodinase-2 Activity and Serum-T3 Levels in Thyroid-Deficient Patients. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1623-1630.	1.8	109
20	Molecular Signature of Indeterminate Thyroid Lesions: Current Methods to Improve Fine Needle Aspiration Cytology (FNAC) Diagnosis. International Journal of Molecular Sciences, 2017, 18, 775.	1.8	18
21	Genetic Heterogeneity of HER2 Amplification and Telomere Shortening in Papillary Thyroid Carcinoma. International Journal of Molecular Sciences, 2016, 17, 1759.	1.8	6
22	Papillary thyroid microcarcinoma: time to shift from surgery to active surveillance?. Lancet Diabetes and Endocrinology, 2016, 4, 933-942.	5.5	200
23	Multifocality in Sporadic Medullary Thyroid Carcinoma: An International Multicenter Study. Thyroid, 2016, 26, 1563-1572.	2.4	36
24	Papillary thyroid microcarcinoma and active surveillance – Authors' reply. Lancet Diabetes and Endocrinology, 2016, 4, 976-977.	5.5	3
25	Obesity Does Not Modify the Risk of Differentiated Thyroid Cancer in a Cytological Series of Thyroid Nodules. European Thyroid Journal, 2016, 5, 125-131.	1.2	25
26	Prospective Study Confirms that Radioiodine Remnant Ablation Is Not Necessary in Low-Risk Differentiated Thyroid Cancer. European Thyroid Journal, 2016, 5, 7-8.	1.2	2
27	Management of advanced medullary thyroid cancer. Lancet Diabetes and Endocrinology, 2016, 4, 64-71.	5.5	100
28	2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid, 2016, 26, 1-133.	2.4	10,674
29	Thyroid Neoplasia. , 2016, , 1601-1628.e10.		1
30	A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment. Cancer, 2015, 121, 2749-2756.	2.0	159
31	Follicular cell-derived thyroid cancer. Nature Reviews Disease Primers, 2015, 1, 15077.	18.1	88
32	IFN- $\gamma$ -Inducible Chemokines Decrease upon Selenomethionine Supplementation in Women with Euthyroid Autoimmune Thyroiditis: Comparison between Two Doses of Selenomethionine (80 or 160 $\mu$ g) versus Placebo. European Thyroid Journal, 2015, 4, 226-233.	1.2	28
33	Break-apart interphase fluorescence in situ hybridization assay in papillary thyroid carcinoma: on the road to optimizing the cut-off level for RET/PTC rearrangements. European Journal of Endocrinology, 2015, 172, 571-582.	1.9	8
34	Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma. Thyroid, 2015, 25, 567-610.	2.4	1,738
35	Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet, 2014, 384, 319-328.	6.3	1,295
36	Circulating miRNA95 and miRNA190 Are Sensitive Markers for the Differential Diagnosis of Thyroid Nodules in a Caucasian Population. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 4190-4198.	1.8	53

#	ARTICLE	IF	CITATIONS
37	Weight Loss Associated with Bariatric Surgery Does Not Restore Short Telomere Length of Severe Obese Patients After 1 Year. <i>Obesity Surgery</i> , 2014, 24, 2089-2093.	1.1	24
38	Definition and management of radioactive iodine-refractory differentiated thyroid cancer. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 356-358.	5.5	283
39	Updated overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib on the phase 3 DECISION trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 6060-6060.	0.8	14
40	Management of Papillary Thyroid Microcarcinoma: Primum Non Nocere!. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 1391-1393.	1.8	21
41	Post-surgical thyroid ablation in intermediate risk-differentiated thyroid cancer patients. <i>European Journal of Endocrinology</i> , 2013, 169, L2.	1.9	0
42	Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients. <i>European Journal of Endocrinology</i> , 2013, 169, 23-29.	1.9	80
43	Patients With Differentiated Thyroid Cancer Who Underwent Radioiodine Thyroid Remnant Ablation With Low-Activity <sup>131</sup> I After Either Recombinant Human TSH or Thyroid Hormone Therapy Withdrawal Showed the Same Outcome After a 10-Year Follow-up. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 2693-2700.	1.8	61
44	How Far Should We Go in the Search and Treatment of Recurrent or Persistent Lymph Node Metastases during Follow-Up of Thyroid Cancer Patients?. <i>European Thyroid Journal</i> , 2013, 2, 145-146.	1.2	3
45	Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 4-4.	0.8	23
46	Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 4-4.	0.8	48
47	Telomere Abnormalities and Chromosome Fragility in Patients Affected by Familial Papillary Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E1327-E1331.	1.8	31
48	Radioactive Iodine Activities for Postsurgical Thyroid Ablation: The Lower the Better. <i>European Thyroid Journal</i> , 2012, 1, 213-215.	1.2	2
49	Optimizing molecular testing in thyroid nodule cytology. <i>Nature Reviews Endocrinology</i> , 2012, 8, 390-391.	4.3	2
50	Approach to and Treatment of Differentiated Thyroid Carcinoma. <i>Medical Clinics of North America</i> , 2012, 96, 369-383.	1.1	61
51	Radioactive iodine-refractory differentiated thyroid cancer: unmet needs and future directions. <i>Expert Review of Endocrinology and Metabolism</i> , 2012, 7, 541-554.	1.2	42
52	Management of differentiated thyroid cancer of the follicular epithelium. <i>Annals of Medicine</i> , 2012, 44, 651-655.	1.5	0
53	Thyroid microcarcinoma. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2012, 26, 381-389.	2.2	32
54	Thyroid microcarcinoma. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2012, 26, 421-429.	2.2	23

#	ARTICLE	IF	CITATIONS
55	Changing natural history of differentiated thyroid cancer. <i>Endocrine</i> , 2012, 42, 229-230.	1.1	12
56	Targeted therapy in refractory thyroid cancer: current achievements and limitations. <i>Future Oncology</i> , 2011, 7, 657-668.	1.1	13
57	Telomere Length in Neoplastic and Nonneoplastic Tissues of Patients with Familial and Sporadic Papillary Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, E1852-E1856.	1.8	28
58	Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine) of Endocrinology, 2011, 165, 441-446.	1.9	243
59	Telomerase and the endocrine system. <i>Nature Reviews Endocrinology</i> , 2011, 7, 420-430.	4.3	12
60	Lack of germline A339V mutation in thyroid transcription factor-1 (TTF-1/NKX2.1) gene in familial papillary thyroid cancer. <i>Thyroid Research</i> , 2010, 3, 4.	0.7	25
61	Impact of Proto-Oncogene Mutation Detection in Cytological Specimens from Thyroid Nodules Improves the Diagnostic Accuracy of Cytology. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 1365-1369.	1.8	295
62	Lack of Association between Urinary Iodine Excretion and Successful Thyroid Ablation in Thyroid Cancer Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 230-237.	1.8	65
63	Are the Clinical and Pathological Features of Differentiated Thyroid Carcinoma Really Changed over the Last 35 Years? Study on 4187 Patients from a Single Italian Institution to Answer this Question. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 1516-1527.	1.8	203
64	Follow-up del paziente con carcinoma differenziato della tiroide secondo le linee di consenso internazionali. <i>L Endocrinologo</i> , 2010, 11, 2-6.	0.0	0
65	Innovazioni nel dosaggio della tireoglobulina circolante nei pazienti con carcinoma differenziato della tiroide. <i>L Endocrinologo</i> , 2010, 11, 248-253.	0.0	0
66	Thyroid Neoplasia. , 2010, , 1668-1701.		1
67	The Low Utility of Pretherapy Scans in Thyroid Cancer Patients. <i>Thyroid</i> , 2009, 19, 815-816.	2.4	15
68	Comment on: Recombinant human TSH in differentiated thyroid cancer: a nuclear medicine perspective. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 329-330.	3.3	3
69	Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer. <i>Thyroid</i> , 2009, 19, 1167-1214.	2.4	6,039
70	Telomeres and Thyroid Cancer. <i>Current Genomics</i> , 2009, 10, 526-533.	0.7	16
71	Diagnosis of medullary thyroid cancer. <i>F1000 Medicine Reports</i> , 2009, 1, .	2.9	1
72	Diagnostic and therapeutic use of recombinant human TSH (rhTSH) in differentiated thyroid cancer. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2008, 22, 1009-1021.	2.2	45

#	ARTICLE	IF	CITATIONS
73	Preface. Best Practice and Research in Clinical Endocrinology and Metabolism, 2008, 22, vii.	2.2	3
74	Expanding Indications for Recombinant Human TSH in Thyroid Cancer. Thyroid, 2008, 18, 687-694.	2.4	22
75	Short Telomeres, Telomerase Reverse Transcriptase Gene Amplification, and Increased Telomerase Activity in the Blood of Familial Papillary Thyroid Cancer Patients. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 3950-3957.	1.8	80
76	How the availability of recombinant human TSH has changed the management of patients who have thyroid cancer. Nature Clinical Practice Endocrinology and Metabolism, 2007, 3, 641-650.	2.9	24
77	Recombinant Human Thyroid-Stimulating Hormone: Use in Papillary and Follicular Thyroid Cancer. Hormone Research in Paediatrics, 2007, 67, 132-142.	0.8	14
78	A Comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-Iodine Administered Doses for Recombinant Thyrotropin-Stimulated Postoperative Thyroid Remnant Ablation in Differentiated Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3542-3546.	1.8	167
79	Clinical Features and Therapeutic Implication of Papillary Thyroid Microcarcinoma. Thyroid, 2007, 17, 1085-1092.	2.4	98
80	Microcarcinoma papillare della tiroide: il pi <sup>131</sup> I frequente dei tumori endocrini. L Endocrinologo, 2007, 8, 94-101.	0.0	0
81	Consenso europeo para el tratamiento de los pacientes con carcinoma tiroideo diferenciado del epitelio folicular. Endocrinología Y Nutricion: Organo De La Sociedad Espanola De Endocrinología Y Nutricion, 2007, 54, 390.e1-390.e16.	0.8	0
82	European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. European Journal of Endocrinology, 2006, 154, 787-803.	1.9	1,804
83	Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. Journal of Nuclear Medicine, 2006, 47, 648-54.	2.8	209
84	rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocrine-Related Cancer, 2005, 12, 49-64.	1.6	154
85	Presurgical Serum Thyroglobulin Has No Prognostic Value in Papillary Thyroid Cancer. Thyroid, 2005, 15, 1041-1045.	2.4	29
86	Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. European Journal of Endocrinology, 2005, 153, 651-659.	1.9	174
87	Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. European Journal of Endocrinology, 2004, 150, 105-112.	1.9	295
88	Impact of Routine Measurement of Serum Calcitonin on the Diagnosis and Outcome of Medullary Thyroid Cancer: Experience in 10,864 Patients with Nodular Thyroid Disorders. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 163-168.	1.8	464
89	Management of thyroid nodules: a clinicopathological, evidence-based approach. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 1443-1449.	3.3	38
90	Authors'™ Response: Should Serum Calcitonin Be Routinely Measured in Patients with Thyroid Nodules? Will the Law Answer before Endocrinologists Do?. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 4770-4770.	1.8	0

#	ARTICLE	IF	CITATIONS
91	L'uso del TSH umano ricombinante (rhTSH) nel follow-up del carcinoma tiroideo differenziato. <i>L'Endocrinologo</i> , 2003, 4, 198-203.	0.0	0
92	Cytotoxic Effects of Carboplatinum and Epirubicin in the Setting of an Elevated Serum Thyrotropin for Advanced Poorly Differentiated Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 4160-4165.	1.8	90
93	Ablation of Thyroid Residues with 30 mCi <sup>131</sup> I: A Comparison in Thyroid Cancer Patients Prepared with Recombinant Human TSH or Thyroid Hormone Withdrawal. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 4063-4068.	1.8	170
94	Follow-up of differentiated thyroid cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2002, 29, S492-S496.	3.3	66
95	CONSENSUS: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 5658-5671.	1.8	1,782
96	Post-surgical ablation of thyroid residues with radioiodine in Ukrainian children and adolescents affected by post-Chernobyl differentiated thyroid cancer. <i>Journal of Endocrinological Investigation</i> , 2001, 24, 445-447.	1.8	11
97	<sup>131</sup> I Therapy for Differentiated Thyroid Cancer Leads to an Earlier Onset of Menopause: Results of a Retrospective Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 3512-3515.	1.8	97
98	Prediction of Disease Status by Recombinant Human TSH-Stimulated Serum Tg in the Postsurgical Follow-Up of Differentiated Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 5686-5690.	1.8	167
99	CONSENSUS: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 5658-5671.	1.8	574
100	Prediction of Disease Status by Recombinant Human TSH-Stimulated Serum Tg in the Postsurgical Follow-Up of Differentiated Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 5686-5690.	1.8	60
101	Suppression of Fas Expression and Down-Regulation of Fas Ligand in Highly Aggressive Human Thyroid Carcinoma. <i>Laboratory Investigation</i> , 2000, 80, 1413-1419.	1.7	26
102	A Comparison of Recombinant Human Thyrotropin and Thyroid Hormone Withdrawal for the Detection of Thyroid Remnant or Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 3877-3885.	1.8	447
103	<sup>131</sup> I Therapy for Elevated Thyroglobulin Levels. <i>Thyroid</i> , 1997, 7, 273-276.	2.4	196
104	Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine. <i>World Journal of Surgery</i> , 1994, 18, 600-604.	0.8	164
105	Thyroid autoantibodies in thyroid cancer: Incidence and relationship with tumour outcome. <i>European Journal of Endocrinology</i> , 1988, 119, 373-380.	1.9	140
106	Unsuspected Parathyroid Cysts Diagnosed by Measurement of Thyroglobulin and Parathyroid Hormone Concentrations in Fluid Aspirates. <i>Annals of Internal Medicine</i> , 1985, 102, 793.	2.0	63